RAFA
Price
$0.09
Change
+$0.01 (+12.50%)
Updated
Sep 3 closing price
Capitalization
8.17M
SBFM
Price
$1.35
Change
-$0.07 (-4.90%)
Updated
Sep 5, 04:55 PM (EDT)
Capitalization
6.17M
67 days until earnings call
Interact to see
Advertisement

RAFA vs SBFM

Header iconRAFA vs SBFM Comparison
Open Charts RAFA vs SBFMBanner chart's image
Rafarma Pharmaceuticals, Inc. (WY)
Price$0.09
Change+$0.01 (+12.50%)
Volume$25.5K
Capitalization8.17M
Sunshine Biopharma
Price$1.35
Change-$0.07 (-4.90%)
Volume$100
Capitalization6.17M
RAFA vs SBFM Comparison Chart in %
Loading...
RAFA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RAFA vs. SBFM commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RAFA is a StrongBuy and SBFM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (RAFA: $0.09 vs. SBFM: $1.43)
Brand notoriety: RAFA and SBFM are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RAFA: 64% vs. SBFM: 118%
Market capitalization -- RAFA: $8.17M vs. SBFM: $6.17M
RAFA [@Pharmaceuticals: Generic] is valued at $8.17M. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $6.17M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RAFA’s FA Score shows that 2 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • RAFA’s FA Score: 2 green, 3 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, RAFA is a better buy in the long-term than SBFM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RAFA’s TA Score shows that 6 TA indicator(s) are bullish while SBFM’s TA Score has 5 bullish TA indicator(s).

  • RAFA’s TA Score: 6 bullish, 3 bearish.
  • SBFM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RAFA is a better buy in the short-term than SBFM.

Price Growth

RAFA (@Pharmaceuticals: Generic) experienced а +42.05% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was -4.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

SBFM is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RAFA($8.17M) has a higher market cap than SBFM($6.17M). RAFA YTD gains are higher at: 20.440 vs. SBFM (-52.333).
RAFASBFMRAFA / SBFM
Capitalization8.17M6.17M132%
EBITDAN/A-6.19M-
Gain YTD20.440-52.333-39%
P/E RatioN/A0.00-
RevenueN/A36.3M-
Total CashN/A10.3M-
Total DebtN/A929K-
FUNDAMENTALS RATINGS
RAFA vs SBFM: Fundamental Ratings
RAFA
SBFM
OUTLOOK RATING
1..100
1513
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
396
PRICE GROWTH RATING
1..100
3984
P/E GROWTH RATING
1..100
286
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBFM's Valuation (40) in the null industry is in the same range as RAFA (71). This means that SBFM’s stock grew similarly to RAFA’s over the last 12 months.

SBFM's Profit vs Risk Rating (100) in the null industry is in the same range as RAFA (100). This means that SBFM’s stock grew similarly to RAFA’s over the last 12 months.

RAFA's SMR Rating (3) in the null industry is significantly better than the same rating for SBFM (96). This means that RAFA’s stock grew significantly faster than SBFM’s over the last 12 months.

RAFA's Price Growth Rating (39) in the null industry is somewhat better than the same rating for SBFM (84). This means that RAFA’s stock grew somewhat faster than SBFM’s over the last 12 months.

RAFA's P/E Growth Rating (2) in the null industry is significantly better than the same rating for SBFM (86). This means that RAFA’s stock grew significantly faster than SBFM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RAFASBFM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RAFA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UNTY52.980.91
+1.75%
Unity Bancorp
TRMK40.780.70
+1.75%
Trustmark Corp
KIM22.790.31
+1.38%
Kimco Realty Corp
SXTP1.480.02
+1.37%
60 Degrees Pharmaceuticals Inc.
ANIX2.97-0.02
-0.67%
Anixa Biosciences

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and ELAN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
N/A
ELAN - SBFM
30%
Poorly correlated
+0.69%
TLRY - SBFM
28%
Poorly correlated
-2.95%
AQST - SBFM
27%
Poorly correlated
+28.10%
CGC - SBFM
26%
Poorly correlated
-1.43%
LFCR - SBFM
25%
Poorly correlated
+2.98%
More